POU5F1

Summary

POU5F1 (POU class 5 homeobox 1, HGNC:9221) is a protein-coding gene on chromosome 6p21.33, encoding POU domain, class 5, transcription factor 1 (Q01860). Transcription factor that binds to the octamer motif (5’-ATTTGCAT-3’). In precision oncology, POU5F1 EXPRESSION is associated with resistance to Oxaliplatin in Colon Cancer (CIViC Level D).

This gene encodes a transcription factor containing a POU homeodomain that plays a key role in embryonic development and stem cell pluripotency. Aberrant expression of this gene in adult tissues is associated with tumorigenesis. This gene can participate in a translocation with the Ewing’s sarcoma gene on chromosome 21, which also leads to tumor formation. Alternative splicing, as well as usage of alternative AUG and non-AUG translation initiation codons, results in multiple isoforms. One of the AUG start codons is polymorphic in human populations. Related pseudogenes have been identified on chromosomes 1, 3, 8, 10, and 12.

Source: NCBI Gene 5460 — RefSeq curated summary.

At a glance

• Gene–disease (curated): primary ovarian failure (Limited, GenCC)
• GWAS associations: 53
• Clinical variants (ClinVar): 24 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Precision-oncology evidence (CIViC): 1 curated variant–drug association
• Transcription factor: yes — 103 downstream targets (CollecTRI)
• MANE Select transcript: NM_002701

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9221
Approved symbol	POU5F1
Name	POU class 5 homeobox 1
Location	6p21.33
Locus type	gene with protein product
Status	Approved
Aliases	OCT3, Oct4, MGC22487, OCT-4, Oct3/4
Ensembl gene	ENSG00000204531
Ensembl biotype	protein_coding
OMIM	164177
Entrez	5460

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 retained_intron

ENST00000259915, ENST00000441888, ENST00000461401, ENST00000471529, ENST00000512818, ENST00000513407, ENST00000606567

RefSeq mRNA: 4 — MANE Select: NM_002701 NM_001173531, NM_001285986, NM_002701, NM_203289

CCDS: CCDS34391, CCDS47398, CCDS75420

Canonical transcript exons

ENST00000259915 — 5 exons

Exon	Start	End
ENSE00001834753	31170216	31170682
ENSE00003605759	31165927	31166047
ENSE00003631186	31165571	31165701
ENSE00003697734	31165128	31165286
ENSE00003736761	31164337	31164867

Expression profiles

Bgee: expression breadth ubiquitous, 132 present calls, max score 96.02.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 3.4348 / max 205.0755, expressed in 109 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
72647	3.3698	109
72646	0.0650	34

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	96.02	gold quality
right uterine tube	UBERON:0001302	87.10	gold quality
metanephros cortex	UBERON:0010533	85.33	gold quality
endometrium	UBERON:0001295	84.22	gold quality
adult mammalian kidney	UBERON:0000082	82.67	gold quality
cortex of kidney	UBERON:0001225	82.12	gold quality
body of pancreas	UBERON:0001150	82.01	gold quality
body of stomach	UBERON:0001161	80.14	gold quality
mucosa of transverse colon	UBERON:0004991	79.75	gold quality
kidney	UBERON:0002113	79.38	gold quality
small intestine Peyer’s patch	UBERON:0003454	78.45	gold quality
small intestine	UBERON:0002108	77.20	gold quality
stomach	UBERON:0000945	76.39	gold quality
fallopian tube	UBERON:0003889	75.71	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	75.50	gold quality
pancreas	UBERON:0001264	75.32	gold quality
left uterine tube	UBERON:0001303	75.29	gold quality
transverse colon	UBERON:0001157	75.25	gold quality
fundus of stomach	UBERON:0001160	74.76	gold quality
right lobe of liver	UBERON:0001114	74.55	gold quality
duodenum	UBERON:0002114	73.72	gold quality
gall bladder	UBERON:0002110	73.17	gold quality
apex of heart	UBERON:0002098	72.93	gold quality
prostate gland	UBERON:0002367	72.89	gold quality
intestine	UBERON:0000160	71.57	gold quality
sural nerve	UBERON:0015488	71.27	gold quality
urinary bladder	UBERON:0001255	70.51	gold quality
colon	UBERON:0001155	70.29	gold quality
endocervix	UBERON:0000458	69.47	gold quality
blood	UBERON:0000178	69.44	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-8271	yes	469.92
E-MTAB-10485	yes	73.79
E-ANND-3	no	1.83

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

103 targets.

Target	Regulation
ACTG2
AFP	Repression
AHR
AKT1	Repression
BACE1-AS	Activation
BIRC5	Activation
BMP4	Repression
BRCA1	Activation
CCN2
CCND1	Unknown
CCNF	Activation
CDH1
CDKN1A	Repression
CDKN2A
CDX2	Repression
CGA	Unknown
CGB3	Repression
CNTF
CXCR4	Activation
DDC	Unknown
DKK1	Repression
DLX5	Repression
DNMT1	Activation
DPPA4	Activation
E2F3	Activation
EED	Unknown
EOMES	Repression
ESRG	Activation
FBXO15	Unknown
FGF4	Activation

JASPAR motifs

Motif	Name	Family
MA1115.1	POU5F1	POU domain factors
MA1115.2	POU5F1	POU domain factors

JASPAR matrix evidence (PMIDs): PMID:23747866

Upstream regulators (CollecTRI, top): CDX2, CEBPD, CRX, CTNNB1, DNMT3A, ELF3, EPAS1, ESRRB, ETV4, EWSR1, FEZF1, FOXC1, FOXD3, FOXO1, GABPA, GSK3B, HDAC1, HIF1A, KLF4, LEF1, MBD2, MBD3, MEIS1, MYBL2, NANOG, NOBOX, NONO, NR0B1, NR2C1, NR2C2, NR2F1, NR2F2, NR2F6, NR5A1, NR5A2, NR6A1, PAX6, PCGF1, POU3F4, POU5F1

miRNA regulators (miRDB)

15 targeting POU5F1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-892A	99.54	68.16	1141
HSA-MIR-3609	99.52	69.89	2587
HSA-MIR-548AH-5P	99.52	69.73	2626
HSA-MIR-103A-2-5P	99.39	67.72	1577
HSA-MIR-3606-5P	99.31	69.67	1168
HSA-MIR-6734-3P	99.15	66.27	1627
HSA-MIR-6815-3P	99.13	68.98	1530
HSA-MIR-299-3P	97.73	66.67	773
HSA-MIR-335-5P	97.10	68.12	1022
HSA-MIR-4654	95.86	65.72	751
HSA-MIR-4769-5P	95.37	66.09	570

Literature-anchored findings (GeneRIF, showing 40)

• FGF4 is upregulated by the OCT3 transcription factor in breast cancer cells. (PMID:12841847)
• Oct4 can dimerize onto DNA in a distinct conformational arrangement. (PMID:12923055)
• Normal pattern of expression is disturbed in dysgenetic gonads, especially in rare intersex cases, thus increasing risk of malignant transformation. High abundance of OCT-3/4 in carcinoma in situ is consistent with early fetal origin and pluripotency. (PMID:15105401)
• Oct4 is required to maintain the undifferentiated stem cell state, and differentiation to trophectoderm occurs in its absence. (PMID:15342930)
• expression of Oct-4 indicates a pluripotent phenotype of CD133(+) cells and appears to be of functional relevance (PMID:15467907)
• Adult stem cells maintain expression of Oct4, consistent with the stem cell hypothesis of carcinogenesis. (PMID:15513931)
• demonstrated changes in DNA methylation in the promoter regions of Nanog and Oct-4 in a human cell line during retinoic acid-induced differentiation (PMID:15615706)
• The Oct4 is an important marker of the undifferentiated state and a central regulator of pluripotency in ES cells. (PMID:15625129)
• Oct-4 mRNA and protein expression during human preimplantation development was studied. (PMID:15695770)
• Gene knockdown of Oct4 promotes differentiation, thereby demonstrating a role for these factors in human embryonic stem cell self-renewal. (PMID:15749924)
• MAPCs express the OCT4 and REX1 transcription factors, two specific markers of undifferentiated embryonic stem (ES) cells. (PMID:15790780)
• Oct-4-mediated transactivation is stimulated by EWS (PMID:15917470)
• The hOct4 promoter upstream region contains multiple regulatory elements, one of which, the GC box, may be an important cis-regulatory element that regulates the transcription of the hOct4 promoter by the binding of Sp family transcription factors. (PMID:16149048)
• The Oct4 protein co-occupy a substantial portion of its target genes, and collaborate to form regulatory circuitry consisting of autoregulatory and feedforward loops. (PMID:16153702)
• results suggest that pseudogenes Oct4-pg5 and Oct4-pg1 may be involved in the regulation of Oct4 gene activity thus might be pertinent to carcinogenesis (PMID:16229821)
• Most stem cell marker Oct-4-expressing cells can be seen in the endometrium at the beginning or middle of the menstrual cycle, mainly in stromal cells. (PMID:16421218)
• data suggest that loss of Oct-3/4 expression leads to induction of a higher apoptotic threshold and to cisplatin resistance in embryonal carcinoma cells of nonseminomatous testicular germ cell tumors (PMID:16557044)
• Expression of POU5F1 isoform A and POU5F1_isoform B was examined in hESCs and all stages of human preimplantation development to look for differences in expression, biological activity, and relation to totipotency. (PMID:16916925)
• DNA binding, transactivation, and abilities to confer self-renewal of the human OCT-4 isoforms differ (PMID:16951404)
• RNA interference-mediated suppression of OCT4 function in a human ESC line and analysis of the resulting transcriptional profiles to identify OCT4-dependent genes in human cells. (PMID:17068183)
• Isolation from cord blood a population of human cells that are similar to murine bone marrow-derived cells containing OCT4. (PMID:17136117)
• OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer (PMID:17205510)
• Data show that Oct-4, Rex-1, and Gata-4 expression in human mesenchymal stem cells increases cell differentiation efficiency but not hTERT expression. (PMID:17211834)
• These data indicate that SF-1 plays a crucial role in the regulation of hOct4 transcription through direct binding to the 1st SF-1 in Conserved Regions 1 of the hOct4 proximal promoter. (PMID:17226773)
• POU5F1 and POU2F subfamily members play a pivotal role for the FZD5 expression in undifferentiated human ES cells, fetal liver/spleen, adult colon, pancreatic islet, and diffuse-type gastric cancer (PMID:17273778)
• genetic association study shows that only a haplotype containing Cw*0602 is strongly associated with psoriasis vulgaris in Chinese; POU5F1 gene is unlikely to be the disease gene at PSORS1 locus (PMID:17314032)
• reprogramming of DNA methylation and histone modifications on regulatory regions of the developmentally regulated OCT4 and NANOG genes (PMID:17314394)
• Human peripheral blood mononuclear cells, genetically stable and mainly terminally differentiated cells with well defined functions and a limited lifespan, express Oct-4. (PMID:17379765)
• WNT8B expression in hepatocyte progenitors derived from human ES cells is due to POU5F1 (OCT3/OCT4) and GATA3, and WNT8B expression in diffuse-type gastric cancer is due to POU5F1 and GATA6 (PMID:17390031)
• Stem cell marker expressed in dental pulp stem cells from 5-7 year olds. (PMID:17409736)
• Our results suggest that an immunohistochemical panel consisting of TTF-1, CEA, CA-125, and OCT-4 is helpful in distinguishing most pulmonary and ovarian carcinomas with clear cell features. (PMID:17413979)
• RNAi-mediated silencing of OCT4 induced differentiation with mesodermal characteristics in EC cells (PMID:17506876)
• sumoylation of Oct4 results in increased stability, DNA binding, and transactivation and provides an important mechanism to regulate Oct4 activity (PMID:17525163)
• Differential methylation of the OCT3/4 upstream region is associated with primary testicular germ cell tumors (PMID:17549357)
• In pluripotent human embryonic stem cells (unlike differentiated hES) Oct4 genes were located on greatly extended chromatin loops, outside their respective chromosome sites, suggesting role in pluripotency of hES. (PMID:17573914)
• possible role of the OCT-4 protein in seminomas (PMID:17682839)
• OCT4 targets similiar genes in mesenchmal and embryonic stem cells and promotes the expression of specific genes and cell cycle progession in each type of cell. (PMID:17761754)
• SARS-infected lung cells express the stem/progenitor cell markers CD34 and Oct-4. (PMID:17923501)
• Both upregulation and downregulation of Oct4 in human embryonic stem cells results in differentiation, but with patterns distinct from parallel experiments in mice. (PMID:17959850)
• OCT4 expression in the cervical carcinoma cell line HeLa and the breast cancer cell line MCF7 was determined in comparison with the human teratoma cell line nTera. (PMID:18032701)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	pou3f1	ENSDARG00000009823
danio_rerio	pou5f3	ENSDARG00000044774
mus_musculus	Pou5f1	ENSMUSG00000024406
rattus_norvegicus	Pou5f1	ENSRNOG00000046487
drosophila_melanogaster	acj6	FBGN0000028
drosophila_melanogaster	vvl	FBGN0086680
caenorhabditis_elegans		WBGENE00000441
caenorhabditis_elegans		WBGENE00006818

Paralogs (17): POU2F2 (ENSG00000028277), POU1F1 (ENSG00000064835), POU4F3 (ENSG00000091010), POU6F2 (ENSG00000106536), POU2F3 (ENSG00000137709), POU2F1 (ENSG00000143190), POU4F2 (ENSG00000151615), POU4F1 (ENSG00000152192), HDX (ENSG00000165259), POU6F1 (ENSG00000184271), POU3F2 (ENSG00000184486), POU3F1 (ENSG00000185668), POU3F4 (ENSG00000196767), POU3F3 (ENSG00000198914), CCDC160 (ENSG00000203952), POU5F1B (ENSG00000212993), POU5F2 (ENSG00000248483)

Protein

Protein identifiers

POU domain, class 5, transcription factor 1 — Q01860 (reviewed: Q01860)

Alternative names: Octamer-binding protein 3, Octamer-binding protein 4, Octamer-binding transcription factor 3

All UniProt accessions (4): D2IYK3, Q01860, F2Z381, M1S623

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor that binds to the octamer motif (5’-ATTTGCAT-3’). Forms a trimeric complex with SOX2 or SOX15 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206. Critical for early embryogenesis and for embryonic stem cell pluripotency.

Subunit / interactions. Interacts with PKM. Interacts with WWP2. Interacts with UBE2I and ZSCAN10. Interacts with PCGF1. Interacts with ESRRB; recruits ESRRB near the POU5F1-SOX2 element in the NANOG proximal promoter; the interaction is DNA independent. Interacts with ZNF322. Interacts with MAPK8 and MAPK9; the interaction allows MAPK8 and MAPK9 to phosphorylate POU5F1 on Ser-355. Interacts (when phosphorylated on Ser-355) with FBXW8. Interacts with FBXW4. Interacts with SOX2 and SOX15; binds synergistically with either SOX2 or SOX15 to DNA. Interacts with DDX56. Interacts with ZNF143; promoting POU5F1/OCT4 association with promoters.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expressed in developing brain. Highest levels found in specific cell layers of the cortex, the olfactory bulb, the hippocampus and the cerebellum. Low levels of expression in adult tissues.

Post-translational modifications. Sumoylation enhances the protein stability, DNA binding and transactivation activity. Sumoylation is required for enhanced YES1 expression. Ubiquitinated; undergoes ‘Lys-63’-linked polyubiquitination by WWP2 leading to proteasomal degradation. ERK1/2-mediated phosphorylation at Ser-111 promotes nuclear exclusion and proteasomal degradation. Phosphorylation at Thr-235 and Ser-236 decrease DNA-binding and alters ability to activate transcription.

Domain organisation. The POU-specific domain mediates interaction with PKM. The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.

Induction. Transcriptional activity is positively regulated by PKM. Upon cell differentiation, expression is repressed by NR6A1.

Miscellaneous. Several pseudogenes of POU5F1 have been described on chromosomes 1, 3, 8, 10 and 12. 2 of them, localized in chromosomes 8 and 10, are transcribed in cancer tissues but not in normal ones and may be involved in the regulation of POU5F1 gene activity in carcinogenesis.

Similarity. Belongs to the POU transcription factor family. Class-5 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q01860-1	A, Oct-3A, Oct3A	yes
Q01860-2	B, Oct-3B, Oct3B

RefSeq proteins (4): NP_001167002, NP_001272915, NP_002692, NP_976034 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000327	POU_dom	Domain
IPR001356	HD	Domain
IPR009057	Homeodomain-like_sf	Homologous_superfamily
IPR010982	Lambda_DNA-bd_dom_sf	Homologous_superfamily
IPR013847	POU	Domain
IPR017970	Homeobox_CS	Conserved_site
IPR050255	POU_domain_TF	Family

Pfam: PF00046, PF00157

UniProt features (38 total): helix 8, sequence conflict 7, modified residue 6, sequence variant 4, region of interest 4, binding site 2, chain 1, domain 1, cross-link 1, splice variant 1, DNA-binding region 1, turn 1, short sequence motif 1

Structure

Experimental structures (PDB)

16 structures.

PDB	Method	Resolution (Å)
8G88	ELECTRON MICROSCOPY	2.3
7U0G	ELECTRON MICROSCOPY	2.6
7U0I	ELECTRON MICROSCOPY	2.6
8SPU	ELECTRON MICROSCOPY	2.8
8SPS	ELECTRON MICROSCOPY	3
6T90	ELECTRON MICROSCOPY	3.05
8G8G	ELECTRON MICROSCOPY	3.2
8OTS	ELECTRON MICROSCOPY	3.3
6YOV	ELECTRON MICROSCOPY	3.42
9RL4	ELECTRON MICROSCOPY	3.5
8G8E	ELECTRON MICROSCOPY	3.9
9RN2	ELECTRON MICROSCOPY	4.1
9RMC	ELECTRON MICROSCOPY	4.2
8G8B	ELECTRON MICROSCOPY	4.3
9RN1	ELECTRON MICROSCOPY	5.9
8G87	ELECTRON MICROSCOPY	8.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q01860-F1	66.31	0.33

Antibody-complex structures (SAbDab): 4 — 7U0G, 7U0I, 8SPS, 8SPU

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 157; 164

Post-translational modifications (7): 111, 235, 236, 289, 290, 355, 123

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-2892245	POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation
R-HSA-2892247	POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
R-HSA-452723	Transcriptional regulation of pluripotent stem cells
R-HSA-9754189	Germ layer formation at gastrulation
R-HSA-9823739	Formation of the anterior neural plate
R-HSA-9827857	Specification of primordial germ cells
R-HSA-9834899	Specification of the neural plate border

MSigDB gene sets: 189 (showing top): GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_SOMATIC_STEM_CELL_POPULATION_MAINTENANCE, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_FGF3, GOBP_FORMATION_OF_PRIMARY_GERM_LAYER, GOBP_DEVELOPMENTAL_INDUCTION, TGACCTY_ERR1_Q2, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, GGGTGGRR_PAX4_03, GOBP_CELL_CELL_SIGNALING, COUP_01, GOBP_ASYMMETRIC_CELL_DIVISION, SMITH_TERT_TARGETS_DN, MUELLER_PLURINET, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT

GO Biological Process (20): negative regulation of transcription by RNA polymerase II (GO:0000122), endodermal cell fate specification (GO:0001714), blastocyst development (GO:0001824), heart induction (GO:0003129), endodermal-mesodermal cell signaling (GO:0003133), regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), response to wounding (GO:0009611), anatomical structure morphogenesis (GO:0009653), regulation of asymmetric cell division (GO:0009786), regulation of gene expression (GO:0010468), BMP signaling pathway (GO:0030509), somatic stem cell population maintenance (GO:0035019), positive regulation of transcription by RNA polymerase II (GO:0045944), cell fate commitment involved in formation of primary germ layer (GO:0060795), cardiac cell fate determination (GO:0060913), positive regulation of canonical Wnt signaling pathway (GO:0090263), negative regulation of miRNA transcription (GO:1902894), positive regulation of gene expression (GO:0010628), negative regulation of gene expression (GO:0010629)

GO Molecular Function (15): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), RNA binding (GO:0003723), ubiquitin protein ligase binding (GO:0031625), miRNA binding (GO:0035198), sequence-specific DNA binding (GO:0043565), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), sequence-specific double-stranded DNA binding (GO:1990837), cis-regulatory region sequence-specific DNA binding (GO:0000987), protein binding (GO:0005515), cytokine binding (GO:0019955)

GO Cellular Component (7): nucleus (GO:0005634), nucleoplasm (GO:0005654), transcription regulator complex (GO:0005667), cytoplasm (GO:0005737), mitochondrion (GO:0005739), cytosol (GO:0005829), chromatin (GO:0000785)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Gastrulation	3
Transcriptional regulation of pluripotent stem cells	2
Developmental Biology	1
Reproduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
regulation of transcription by RNA polymerase II	3
transcription by RNA polymerase II	3
regulation of gene expression	3
gene expression	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
negative regulation of DNA-templated transcription	2
anatomical structure development	2
regulation of DNA-templated transcription	2
nucleic acid binding	2
transcription cis-regulatory region binding	2
intracellular membrane-bounded organelle	2
cytoplasm	2
cell fate specification	1
endodermal cell fate commitment	1
in utero embryonic development	1
organ induction	1
heart field specification	1
regulation of heart morphogenesis	1
cell-cell signaling	1
DNA-templated transcription	1
regulation of RNA biosynthetic process	1
response to stress	1
developmental process	1
asymmetric cell division	1
regulation of cell division	1
regulation of macromolecule biosynthetic process	1
cellular response to BMP stimulus	1
transforming growth factor beta receptor superfamily signaling pathway	1
stem cell population maintenance	1
positive regulation of DNA-templated transcription	1
formation of primary germ layer	1
cell fate commitment	1
cell fate determination	1
cardiac cell fate commitment	1
positive regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of canonical Wnt signaling pathway	1
miRNA transcription	1
regulation of miRNA transcription	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

50 interactions, top by confidence:

A	B	Type	Score
WWP2	POU5F1	psi-mi:“MI:0407”(direct interaction)	0.650
POU5F1	WWP2	psi-mi:“MI:0915”(physical association)	0.650
POU5F1	WWP2	psi-mi:“MI:0220”(ubiquitination reaction)	0.650
Hmgb1	POU5F1	psi-mi:“MI:0915”(physical association)	0.590
POU5F1	Hmgb1	psi-mi:“MI:0915”(physical association)	0.590
POU5F1		psi-mi:“MI:0915”(physical association)	0.560
SOX2	POU5F1	psi-mi:“MI:0914”(association)	0.560
	POU5F1	psi-mi:“MI:0914”(association)	0.560
POU5F1	SOX2	psi-mi:“MI:0915”(physical association)	0.560
POU5F1		psi-mi:“MI:0914”(association)	0.560
POU5F1	NANOG	psi-mi:“MI:0915”(physical association)	0.520
FOXD3	POU5F1	psi-mi:“MI:0915”(physical association)	0.520
POU5F1	FOXD3	psi-mi:“MI:0915”(physical association)	0.520
	POU5F1	psi-mi:“MI:0915”(physical association)	0.520
E1A	POU5F1	psi-mi:“MI:0915”(physical association)	0.520
MBD3	KLF4	psi-mi:“MI:0914”(association)	0.500
MBD3	POU5F1	psi-mi:“MI:0915”(physical association)	0.500
KPNA2	POU5F1	psi-mi:“MI:0914”(association)	0.460
L1TD1	PARP1	psi-mi:“MI:0914”(association)	0.460
POU5F1	LRRK2	psi-mi:“MI:0407”(direct interaction)	0.440
GMNN	POU5F1	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (386): POU5F1 (Affinity Capture-Western), CTNNB1 (Affinity Capture-Western), POU5F1 (Affinity Capture-Western), DTYMK (Affinity Capture-MS), ABCF1 (Affinity Capture-MS), ACACB (Affinity Capture-MS), ACOT9 (Affinity Capture-MS), ANAPC4 (Affinity Capture-MS), ANGEL2 (Affinity Capture-MS), AP3D1 (Affinity Capture-MS), API5 (Affinity Capture-MS), ARID1B (Affinity Capture-MS), ARMCX1 (Affinity Capture-MS), ATG101 (Affinity Capture-MS), ATP5A1 (Affinity Capture-MS)

ESM2 similar proteins: A1YER7, A1YF08, A1YFY3, A1YG85, A2T6X6, A2T756, A7Y7W2, O02786, O42230, O43711, O55144, O57601, O93367, O97552, P13297, P20263, P28360, P31277, P36402, P42582, P50223, P52945, P52946, P52947, P70118, P70354, P79772, Q01860, Q06416, Q12952, Q14549, Q2VL76, Q2VL77, Q2VL78, Q2VL79, Q2VL80, Q2VL82, Q2VL83, Q2VL84, Q2VL85

Diamond homologs: A0A1L8FFY5, A1L0Z1, A7Y7W2, B3DM23, B3DM25, B7ZQA9, D3ZTL1, G3V7L5, O97552, P09086, P10036, P10037, P13528, P14859, P15143, P16143, P16241, P17208, P20263, P20264, P20265, P20266, P20267, P20268, P20912, P20913, P20914, P21952, P24350, P25425, P28069, P31360, P31361, P31362, P31363, P31364, P31365, P31367, P31368, P31369

SIGNOR signaling

55 interactions.

A	Effect	B	Mechanism
MAPK1	down-regulates	POU5F1	phosphorylation
MAPK3	down-regulates	POU5F1	phosphorylation
ETV4	“up-regulates quantity by expression”	POU5F1	“transcriptional regulation”
POU5F1	up-regulates	Pluripotency
AKT	“up-regulates quantity by stabilization”	POU5F1	phosphorylation
AKT2	“up-regulates quantity by stabilization”	POU5F1	phosphorylation
POU5F1	“down-regulates quantity by repression”	AKT	“transcriptional regulation”
AKT3	“up-regulates quantity by stabilization”	POU5F1	phosphorylation
AKT1	“up-regulates quantity by stabilization”	POU5F1	phosphorylation
POU5F1	“down-regulates quantity by repression”	AKT1	“transcriptional regulation”
POU5F1	“up-regulates quantity by expression”	DNMT1	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	GATA6	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	GATA4	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	PAX6	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	FOXA2	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	SOX17	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	TBXT	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	EOMES	“transcriptional regulation”
POU5F1	“up-regulates quantity by expression”	THY1	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	BMP4	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	CDX2	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	DKK1	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	DLX5	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	HLX	“transcriptional regulation”
POU5F1	“down-regulates quantity by repression”	ID2	“transcriptional regulation”
POU5F1	“up-regulates quantity by expression”	LEFTY1	“transcriptional regulation”
POU5F1	“up-regulates quantity by expression”	NANOG	“transcriptional regulation”
POU5F1	“up-regulates quantity by expression”	LEFTY2	“transcriptional regulation”
POU5F1	“up-regulates quantity by expression”	DPPA4	“transcriptional regulation”

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

24 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	12
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

863 predictions. Top by Δscore:

Variant	Effect	Δscore
6:31164864:CCAC:C	acceptor_gain	1.0000
6:31164865:CAC:C	acceptor_gain	1.0000
6:31164865:CACC:C	acceptor_gain	1.0000
6:31164867:CCT:C	acceptor_loss	1.0000
6:31164868:C:CC	acceptor_gain	1.0000
6:31164874:G:C	acceptor_gain	1.0000
6:31165123:CTCA:C	donor_loss	1.0000
6:31165124:TCACA:T	donor_loss	1.0000
6:31165125:CACAT:C	donor_loss	1.0000
6:31165126:A:AC	donor_gain	1.0000
6:31165126:ACAT:A	donor_gain	1.0000
6:31165126:ACATC:A	donor_gain	1.0000
6:31165127:C:CG	donor_gain	1.0000
6:31165127:CAT:C	donor_gain	1.0000
6:31165127:CATC:C	donor_gain	1.0000
6:31165127:CATCC:C	donor_gain	1.0000
6:31165129:T:TA	donor_gain	1.0000
6:31165282:CATAT:C	acceptor_gain	1.0000
6:31165565:CCTTA:C	donor_loss	1.0000
6:31165566:CTTAC:C	donor_loss	1.0000
6:31165567:TTA:T	donor_loss	1.0000
6:31165568:TA:T	donor_loss	1.0000
6:31165569:A:T	donor_loss	1.0000
6:31165569:ACCT:A	donor_gain	1.0000
6:31165570:C:A	donor_loss	1.0000
6:31165570:CCTC:C	donor_gain	1.0000
6:31165572:T:TA	donor_gain	1.0000
6:31165599:T:TA	donor_gain	1.0000
6:31165699:TCC:T	acceptor_gain	1.0000
6:31165700:CC:C	acceptor_gain	1.0000

AlphaMissense

2311 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:31164835:C:A	Q283H	1.000
6:31164835:C:G	Q283H	1.000
6:31164840:G:T	R282S	1.000
6:31164844:G:C	N280K	1.000
6:31164844:G:T	N280K	1.000
6:31164846:T:C	N280D	1.000
6:31164847:A:C	C279W	1.000
6:31164848:C:T	C279Y	1.000
6:31164849:A:G	C279R	1.000
6:31164850:G:C	F278L	1.000
6:31164850:G:T	F278L	1.000
6:31164851:A:C	F278C	1.000
6:31164851:A:G	F278S	1.000
6:31164852:A:C	F278V	1.000
6:31164852:A:G	F278L	1.000
6:31164852:A:T	F278I	1.000
6:31164853:C:A	W277C	1.000
6:31164853:C:G	W277C	1.000
6:31164855:A:G	W277R	1.000
6:31164855:A:T	W277R	1.000
6:31164857:A:G	V276A	1.000
6:31164863:A:T	V274D	1.000
6:31165153:G:T	A264D	1.000
6:31165180:G:T	P255H	1.000
6:31165181:G:A	P255S	1.000
6:31165181:G:T	P255T	1.000
6:31165197:G:C	F249L	1.000
6:31165197:G:T	F249L	1.000
6:31165199:A:G	F249L	1.000
6:31165210:A:G	L245P	1.000

dbSNP variants (sampled 300 via entrez): RS1000615578 (6:31164140 A>G), RS1001282425 (6:31167846 G>A,C,T), RS1001547868 (6:31165347 C>G,T), RS1001781252 (6:31172372 TG>T), RS1002148625 (6:31172617 AG>A), RS1002211292 (6:31166434 G>A), RS1002424092 (6:31172567 C>T), RS1003781537 (6:31169293 T>C,G), RS1004473699 (6:31167283 T>C), RS1004566652 (6:31169432 T>A), RS1004903094 (6:31172587 G>A), RS1004967395 (6:31167375 C>A), RS1005156071 (6:31167769 G>T), RS1005691978 (6:31170969 T>C), RS1006234562 (6:31169039 A>G)

Disease associations

OMIM: gene MIM:164177 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
primary ovarian failure	Limited	Autosomal dominant

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

53 associations (top):

Study	Trait	p-value
GCST001181_4	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)	2.000000e-08
GCST001181_5	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)	8.000000e-07
GCST001181_6	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)	3.000000e-08
GCST001239_1	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	2.000000e-08
GCST002140_3	Multiple myeloma	1.000000e-10
GCST002352_17	Type 2 diabetes	4.000000e-09
GCST003542_141	Night sleep phenotypes	5.000000e-06
GCST004131_25	Inflammatory bowel disease	2.000000e-31
GCST004133_79	Ulcerative colitis	5.000000e-65
GCST004521_103	Autism spectrum disorder or schizophrenia	2.000000e-08
GCST004521_107	Autism spectrum disorder or schizophrenia	2.000000e-08
GCST004521_114	Autism spectrum disorder or schizophrenia	3.000000e-17
GCST004521_117	Autism spectrum disorder or schizophrenia	3.000000e-15
GCST004521_124	Autism spectrum disorder or schizophrenia	3.000000e-12
GCST004521_126	Autism spectrum disorder or schizophrenia	2.000000e-10
GCST004521_132	Autism spectrum disorder or schizophrenia	2.000000e-09
GCST004521_16	Autism spectrum disorder or schizophrenia	2.000000e-12
GCST004521_167	Autism spectrum disorder or schizophrenia	4.000000e-16
GCST004521_19	Autism spectrum disorder or schizophrenia	2.000000e-12
GCST004521_209	Autism spectrum disorder or schizophrenia	5.000000e-16
GCST004521_210	Autism spectrum disorder or schizophrenia	5.000000e-15
GCST004521_211	Autism spectrum disorder or schizophrenia	5.000000e-15
GCST004521_213	Autism spectrum disorder or schizophrenia	5.000000e-13
GCST004521_229	Autism spectrum disorder or schizophrenia	4.000000e-11
GCST004521_257	Autism spectrum disorder or schizophrenia	6.000000e-10
GCST004521_265	Autism spectrum disorder or schizophrenia	7.000000e-14
GCST004521_27	Autism spectrum disorder or schizophrenia	1.000000e-09
GCST004521_282	Autism spectrum disorder or schizophrenia	5.000000e-09
GCST004521_295	Autism spectrum disorder or schizophrenia	6.000000e-18
GCST004521_3	Autism spectrum disorder or schizophrenia	2.000000e-15

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004587	lymphocyte count
EFO:0008402	susceptibility to cold sores measurement
EFO:0008039	BMI-adjusted hip circumference
EFO:0007788	BMI-adjusted waist-hip ratio

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3580526 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 66,828 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL902	FAMOTIDINE	4	66,828

Clinical evidence (CIViC)

Drug × variant × indication: 1 predictive associations from 1 curated evidence items.

Variant	Therapy	Indication	Effect	Level	CIViC
POU5F1 EXPRESSION	Oxaliplatin	Colon Cancer	Resistance	CIViC D	EID958

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

2 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs3130501	Toxicity	3	allopurinol	Severe Cutaneous Adverse Reactions;Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis
rs3130931	Toxicity	3	allopurinol	Severe Cutaneous Adverse Reactions;Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3130501	POU5F1	3	0.00	1	allopurinol
rs3130931	POU5F1, TCF19	3	0.00	1	allopurinol

Binding affinities (BindingDB)

3 measured of 3 human assays (3 total across all organisms); most potent 3 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
N-[2-[(2-fluorophenyl)methylsulfanyl]ethyl]-7-methyl-2,3-dihydroimidazo[1,2-a]pyridine-2-carboxamide	IC50	8200 nM	US-10149840: OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent
2-[[1-(2-ethoxyphenyl)tetrazol-5-yl]sulfanylmethyl]-6-methylimidazo[1,2-a]pyridine	IC50	25300 nM	US-10149840: OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent
CHEBI:4975	IC50	67600 nM	US-10149840: OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent

ChEMBL bioactivities

1 potent at pChembl≥5 of 3 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.09	IC50	8200	nM	CHEMBL5797734

CTD chemical–gene interactions

151 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, decreases reaction, affects expression, increases expression, increases reaction (+2 more)	9
Cisplatin	affects cotreatment, increases expression, decreases response to substance, affects expression, affects response to substance	7
Tretinoin	affects expression, decreases expression	7
Valproic Acid	affects cotreatment, decreases expression, decreases reaction, increases expression	7
bisphenol A	affects binding, decreases reaction, affects expression, affects reaction, affects cotreatment (+3 more)	5
Estradiol	affects cotreatment, increases expression, affects binding, increases reaction, decreases reaction	5
Arsenic Trioxide	increases expression, increases reaction, decreases expression, affects reaction	4
methylmercuric chloride	increases expression	3
trichostatin A	affects expression, increases reaction, increases expression	3
diallyl trisulfide	increases expression, decreases expression, increases abundance	3
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases reaction, affects cotreatment, decreases expression, increases reaction	3
Chir 99021	affects cotreatment, decreases expression, affects binding, increases expression	3
bisphenol S	affects cotreatment, increases expression, decreases expression	3
LDN 193189	affects cotreatment, decreases expression, increases reaction, decreases reaction	3
Resveratrol	decreases expression, affects cotreatment	3
Acetylcysteine	decreases expression, decreases reaction	3
Arsenic	affects methylation, affects cotreatment, increases expression	3
Ascorbic Acid	affects binding, affects cotreatment, decreases expression, decreases reaction, increases expression	3
Lithium Chloride	decreases expression, decreases reaction, affects reaction, increases expression, increases reaction	3
Particulate Matter	decreases expression, decreases reaction, increases expression	3
kaempferol	affects cotreatment, decreases expression	2
nickel chloride	increases expression, increases reaction, increases stability	2
ovatodiolide	decreases reaction, decreases expression	2
XAV939	affects cotreatment, decreases expression, decreases reaction, increases expression, affects binding	2
(+)-JQ1 compound	affects binding, decreases reaction, decreases expression	2
Ethanol	decreases expression, increases expression, decreases reaction	2
Benzo(a)pyrene	affects cotreatment, increases expression, increases reaction, increases methylation	2
Diethylhexyl Phthalate	affects cotreatment, decreases expression, decreases reaction, increases expression	2
Oxygen	decreases expression, increases expression	2
Paraquat	affects expression, affects reaction, increases expression	2

ChEMBL screening assays

36 unique, capped per target: 36 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3583934	Binding	Activation of human Oct3/4 in HEK293 cells transfected with firefly luciferase gene assessed as luciferase signal by luminometer plate reader relative to DMSO control	Identification of 2-[4-[(4-Methoxyphenyl)methoxy]-phenyl]acetonitrile and Derivatives as Potent Oct3/4 Inducers. — J Med Chem

Cellosaurus cell lines

7 cell lines: 4 cancer cell line, 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A5N1	SEES3-1V human POU5F1, clone1	Embryonic stem cell	Male
CVCL_A5N2	SEES3-1V human POU5F1, clone2	Embryonic stem cell	Male
CVCL_A5N3	SEES3-1V human POU5F1, clone3	Embryonic stem cell	Male
CVCL_B8MU	Abcam HCT 116 POU5F1 KO	Cancer cell line	Male
CVCL_B9AH	Abcam MCF-7 POU5F1 KO	Cancer cell line	Female
CVCL_B9Q3	Abcam A-549 POU5F1 KO	Cancer cell line	Male
CVCL_C3GF	GBS6	Cancer cell line	Female

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists